Topoisomerase-I inhibitors in gynecologic tumors

P. Haluska, E. Rubin, C. F. Verschraegen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The first section of this article reviews recent studies that have clarified both the cellular role of topoisomerase I and the mechanisms of cytotoxicity of the topoisomerase inhibitors, the camptothecins. Different analogs of this new class of antitumor drug have been studied using various dose schedules in the treatment of refractory or recurrent gynecologic cancer. Response rates are between 13% and 25%. The main toxic effects are hematologic and gastrointestinal, the latter remains problematic. Radiotherapy, alkylate, platinum analogues, and topoisomerase II inhibitors are currently being studied in combination with camptothecins.

Original languageEnglish (US)
Pages (from-to)43-61
Number of pages19
JournalHematology/Oncology Clinics of North America
Volume13
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Topoisomerase I Inhibitors
Camptothecin
Topoisomerase Inhibitors
Topoisomerase II Inhibitors
Type I DNA Topoisomerase
Poisons
Platinum
Antineoplastic Agents
Neoplasms
Appointments and Schedules
Radiotherapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Topoisomerase-I inhibitors in gynecologic tumors. / Haluska, P.; Rubin, E.; Verschraegen, C. F.

In: Hematology/Oncology Clinics of North America, Vol. 13, No. 1, 1999, p. 43-61.

Research output: Contribution to journalArticle

Haluska, P. ; Rubin, E. ; Verschraegen, C. F. / Topoisomerase-I inhibitors in gynecologic tumors. In: Hematology/Oncology Clinics of North America. 1999 ; Vol. 13, No. 1. pp. 43-61.
@article{599a528a0f7e49c9bfa4eaf96200fc98,
title = "Topoisomerase-I inhibitors in gynecologic tumors",
abstract = "The first section of this article reviews recent studies that have clarified both the cellular role of topoisomerase I and the mechanisms of cytotoxicity of the topoisomerase inhibitors, the camptothecins. Different analogs of this new class of antitumor drug have been studied using various dose schedules in the treatment of refractory or recurrent gynecologic cancer. Response rates are between 13{\%} and 25{\%}. The main toxic effects are hematologic and gastrointestinal, the latter remains problematic. Radiotherapy, alkylate, platinum analogues, and topoisomerase II inhibitors are currently being studied in combination with camptothecins.",
author = "P. Haluska and E. Rubin and Verschraegen, {C. F.}",
year = "1999",
doi = "10.1016/S0889-8588(05)70153-2",
language = "English (US)",
volume = "13",
pages = "43--61",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Topoisomerase-I inhibitors in gynecologic tumors

AU - Haluska, P.

AU - Rubin, E.

AU - Verschraegen, C. F.

PY - 1999

Y1 - 1999

N2 - The first section of this article reviews recent studies that have clarified both the cellular role of topoisomerase I and the mechanisms of cytotoxicity of the topoisomerase inhibitors, the camptothecins. Different analogs of this new class of antitumor drug have been studied using various dose schedules in the treatment of refractory or recurrent gynecologic cancer. Response rates are between 13% and 25%. The main toxic effects are hematologic and gastrointestinal, the latter remains problematic. Radiotherapy, alkylate, platinum analogues, and topoisomerase II inhibitors are currently being studied in combination with camptothecins.

AB - The first section of this article reviews recent studies that have clarified both the cellular role of topoisomerase I and the mechanisms of cytotoxicity of the topoisomerase inhibitors, the camptothecins. Different analogs of this new class of antitumor drug have been studied using various dose schedules in the treatment of refractory or recurrent gynecologic cancer. Response rates are between 13% and 25%. The main toxic effects are hematologic and gastrointestinal, the latter remains problematic. Radiotherapy, alkylate, platinum analogues, and topoisomerase II inhibitors are currently being studied in combination with camptothecins.

UR - http://www.scopus.com/inward/record.url?scp=0033044401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033044401&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70153-2

DO - 10.1016/S0889-8588(05)70153-2

M3 - Article

C2 - 10080069

AN - SCOPUS:0033044401

VL - 13

SP - 43

EP - 61

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 1

ER -